4 Types of Leukemia Explained: ALL, AML, CLL & CML

Leukemia is not a single disease but a family of blood cancers split along two axes: how fast the abnormal cells grow (acute versus chronic) and which type of blood cell they arise from (lymphoid versus myeloid). Those two distinctions produce the four major types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Each behaves differently, strikes different age groups, and responds to very different treatments, so understanding which type someone has matters enormously for what comes next.

How the Four Types Are Sorted

Blood cells are made in the bone marrow from stem cells that mature along two main paths. One path produces lymphoid cells, which become the B cells and T cells of the immune system. The other produces myeloid cells, which become red blood cells, platelets, and certain white blood cells like neutrophils. When something goes wrong in either lineage, the result is leukemia, but the “which lineage” question determines whether it’s classified as lymphocytic (or lymphoblastic) or myeloid.

The second question is speed. In acute leukemias, immature cells multiply fast and crowd out normal blood cells within weeks if left untreated. In chronic leukemias, the abnormal cells are more mature, accumulate slowly, and people can live for years before symptoms force a treatment decision. Combine those two axes and you get four quadrants: ALL (acute + lymphoid), AML (acute + myeloid), CLL (chronic + lymphoid), and CML (chronic + myeloid). The rate at which leukemic cells double varies wildly even within a single type. One early study of acute myeloid leukemia found that some patients’ leukemic burden doubled in roughly 16 hours, while in others it took about eight days.¹

Acute Lymphoblastic Leukemia

ALL is the classic childhood leukemia. It arises when lymphoid progenitor cells in the bone marrow begin multiplying rapidly without ever maturing into functional immune cells.² The most common form, B-cell ALL, involves the lineage that normally produces antibodies. A smaller fraction arises from the T-cell lineage. Several genetic abnormalities drive the disease, and which ones are present has a strong influence on prognosis.

The good news is that ALL in children has become one of oncology’s genuine success stories. Where decades ago fewer than one in nine children survived, today close to 90% achieve long-term survival.³ Adults with ALL fare considerably worse, a gap driven by differences in disease biology, tolerance for intensive chemotherapy, and the frequency of high-risk genetic subtypes.

One complication particular to ALL is its tendency to hide in the central nervous system. The brain and spinal cord are “sanctuary sites” where standard chemotherapy has trouble reaching, so leukemic cells can persist there even when the blood and marrow look clean. CNS involvement carries a poor prognosis, and preventing it requires injecting chemotherapy directly into the spinal fluid, a strategy called intrathecal prophylaxis.⁴ Even with prophylaxis, some patients still experience CNS relapses, though the use of radiation therapy for this purpose has been declining over time.⁵

For patients whose B-cell ALL comes back after initial treatment or doesn’t respond to chemotherapy, CAR T-cell therapy has rapidly become a standard option. In this approach, a patient’s own immune cells are genetically engineered to recognize and attack leukemic cells by targeting a surface marker called CD19. For T-cell ALL, though, developing CAR T-cell therapies is harder because the leukemic cells lack the surface markers that current CAR products are designed to find. New approaches targeting T-cell-specific molecules are in early clinical testing.⁶

Acute Myeloid Leukemia

AML is defined by the uncontrolled growth of immature myeloid cells that fail to differentiate into functional blood cells.⁷ Unlike ALL, which peaks in young children, AML predominantly affects older adults, and its global share of total leukemia cases has been rising: it accounted for about 18% of all leukemia worldwide in 1990 and roughly 23% by 2017.⁸

AML is genetically diverse. Dozens of different mutations can initiate or sustain the disease, and identifying which mutations are present shapes treatment choices. The most commonly mutated gene in AML is NPM1, found in roughly 30% of cases. NPM1 mutations cause a key protein to end up in the wrong part of the cell, where it blocks normal maturation, promotes cell growth, and impairs the cell’s ability to repair DNA damage.⁹ While NPM1 mutation is generally considered a favorable prognostic sign, some patients still relapse or fail to respond, so the search for targeted therapies aimed at this mutation is ongoing.

Treatment for AML typically involves intensive chemotherapy aimed at wiping out the leukemic cells and then, in many cases, a bone marrow transplant to rebuild the blood system from scratch. Older patients who cannot tolerate aggressive chemotherapy may receive lower-intensity regimens combined with newer targeted drugs. Survival rates vary enormously depending on the specific genetic subtype, the patient’s age, and how the leukemia responds to initial treatment.

Chronic Lymphocytic Leukemia

CLL is the most frequently diagnosed blood cancer in adults in much of the Western world.¹⁰ It involves the slow buildup of mature-looking but dysfunctional B cells in the blood, bone marrow, and lymph nodes.¹¹ CLL sits on a wide clinical spectrum: some people have a gently rising white blood cell count that never causes problems, while others develop aggressive disease that needs prompt treatment.¹²

The biggest psychological hurdle for many CLL patients is the “watch and wait” approach. At diagnosis, the majority of patients don’t need treatment right away. Clinical trials in the 1990s showed that starting chemotherapy early in asymptomatic patients didn’t help them live longer and actually increased side effects.¹² Up to 30% of CLL patients never need treatment in their lifetime.¹⁰ Being told you have cancer but that the best course of action is to do nothing provokes understandable anxiety, and research into the psychological toll of this approach has become a focus in its own right.

When CLL does need treatment, the landscape has been transformed by targeted drugs. BTK inhibitors like ibrutinib block a signaling pathway that CLL cells depend on for survival, while BCL-2 inhibitors like venetoclax trigger the self-destruction mechanism that the leukemic cells have learned to suppress. The combination of venetoclax and ibrutinib was listed as a first-line treatment option in the 2024 European guidelines, and newer agents in both classes are being studied to improve outcomes further.¹³ These drugs have been a genuine revolution for CLL, extending survival even in patients whose disease had stopped responding to older chemotherapy regimens.

Chronic Myeloid Leukemia

CML holds a special place in cancer biology because it has a single, near-universal genetic cause. All CML patients carry what is known as the Philadelphia chromosome, a piece of chromosome 9 that has swapped places with a piece of chromosome 22.¹⁴ This swap creates a fusion gene called BCR-ABL, which produces an enzyme that is stuck permanently in the “on” position, driving bone marrow cells to multiply without the usual stop signals.¹⁵

Because the target is so clearly defined, CML became the proving ground for precision medicine. Tyrosine kinase inhibitors, drugs designed specifically to block the BCR-ABL enzyme, have turned CML from a disease with a median survival of a few years into one where most patients live about as long as people without leukemia.¹⁶ The first of these drugs, imatinib, arrived in 2001 and was soon followed by second- and third-generation versions for patients who didn’t respond to or couldn’t tolerate the original.

A question CML patients increasingly ask is whether they can stop taking their medication. Some patients who achieve a deep and sustained molecular response, meaning their BCR-ABL levels have been undetectable for an extended period, are candidates for attempting treatment-free remission. Across studies, roughly 38 to 54% of selected patients manage to stay in remission after stopping their TKI.¹⁶ Those who relapse almost always respond again when they restart the drug. In practice, though, only about half of all CML patients become eligible to try stopping, and of those, only about half succeed long-term. That means roughly 20% of newly diagnosed CML patients ultimately achieve lasting treatment-free remission, while the majority need to continue their medication indefinitely.¹⁷

Globally, CML incidence has actually been declining. The age-standardized incidence rate fell from about 0.75 per 100,000 in 1990 to roughly 0.43 per 100,000 in 2017, with decreases observed across most of the world.⁸

Why Children with ALL Do So Much Better Than Adults

The outcome gap between children and adults with ALL is striking enough to deserve its own explanation. Nearly 90% of children now achieve long-term survival, while adults lag far behind.³ There is no single reason. The biology of the disease itself is different: children are more likely to carry genetic abnormalities associated with a good prognosis, while adults more often harbor high-risk features. Children tolerate intensive chemotherapy better because their organs are healthier and more resilient. They are also more likely to be treated on clinical trial protocols, which tend to produce better outcomes than ad hoc treatment approaches.

An in-between group, adolescents and young adults, has drawn particular attention. Studies have repeatedly shown that teenagers treated on pediatric-style protocols do better than those treated on adult protocols, even when the biology of their leukemia looks the same. This has pushed many cancer centers to treat patients in their late teens and twenties using the more intensive pediatric approach rather than the traditional adult regimen. The practical ceiling is somewhere around age 40 or so, beyond which the toxicity of pediatric-intensity chemotherapy becomes too much for most patients to handle safely.

When Leukemia Is Caused by Prior Cancer Treatment

Not all leukemias arise out of nowhere. A subset, known as therapy-related myeloid neoplasms, develops in people who previously received chemotherapy, radiation, or immunosuppressive drugs for another cancer or even for a non-cancerous condition. These secondary leukemias almost always fall into the myeloid category, typically AML or a related condition called myelodysplastic syndrome.¹⁸

The specific chromosomal damage found in these cases often reflects which treatment triggered them. Alkylating agents, a class of older chemotherapy drugs, tend to produce deletions on chromosomes 5 and 7. Topoisomerase II inhibitors, another chemotherapy class, are associated with rearrangements involving chromosomes 11 and 21.¹⁸ Even radiation therapy alone can do it: a study of patients who developed myeloid neoplasms after radiation without chemotherapy found that 45% had abnormalities involving chromosomes 5, 7, or both.¹⁹ Benzene exposure produces similar chromosomal patterns, blurring the line between occupational and treatment-related disease.

Therapy-related AML is generally harder to treat than AML that arises on its own. Patients are often older, their bone marrow has already been damaged by prior treatment, and the genetic makeup of the leukemia tends to be high-risk. This is a genuine trade-off that oncologists weigh when designing treatment for the original cancer: the regimen that gives the best chance of curing one disease may carry a small but real risk of causing another one years later.

How Leukemia Is Diagnosed

All four types share some diagnostic tools, but the specific workup depends on which type is suspected. The starting point is usually a routine blood test that reveals an abnormal white blood cell count, unusual-looking cells on a blood smear, or unexplained anemia or low platelets. From there, a bone marrow biopsy provides the definitive picture. A needle is used to extract a small core of marrow and a liquid sample, and both are examined under the microscope and subjected to further testing.²⁰

Flow cytometry is particularly important for the lymphoid leukemias. This technology identifies cells by the specific surface markers they carry. CLL cells, for instance, display a characteristic combination of markers that allows a confident diagnosis in most cases.²¹ For CML, the critical test is confirming the presence of the Philadelphia chromosome, done through cytogenetic analysis or molecular testing for the BCR-ABL fusion gene. AML classification has become heavily genetic: identifying the specific mutations present at diagnosis is now essential for choosing the right treatment.

Shifting Incidence Patterns Around the World

The four leukemia types are not holding steady. Between 1990 and 2017, global trends moved in different directions for each. ALL case counts rose from about 49,000 to 64,000 per year, though age-adjusted rates were essentially flat or slightly declining. CLL cases more than doubled, with rising rates in over 85% of countries studied. AML’s share of all leukemia grew from 18% to 23%, and its rates were climbing across more than 120 countries. CML, by contrast, showed declining rates in most of the world.⁸

In the United States specifically, birth-cohort analysis has revealed interesting patterns. Among men born since 1946, CLL incidence has been decreasing while AML incidence has been increasing, with shifts on the order of about 1% per birth year.²² The reasons behind these generational shifts are not fully understood. Changes in environmental exposures, diagnostic practices, and population aging all play roles, but untangling which factor matters most for each leukemia type remains an open question.

The Emotional Weight of a Chronic Diagnosis

People sometimes assume that a “chronic” leukemia diagnosis is the easy one. And it is true that CLL and CML carry better overall prognoses than their acute counterparts. But living with a cancer diagnosis that may stretch across decades brings its own burden. Research on CLL patients in the Netherlands found that their quality of life was measurably worse than the general population’s, even among those who had not yet started treatment. Fatigue, sleep disturbance, breathlessness, and financial difficulties all scored worse than population norms, and quality of life dropped further at every stage of treatment.²³

For CML patients, the shift from a fatal diagnosis to a lifelong pill regimen has been a medical triumph, but it comes with chronic side effects like fatigue, muscle cramps, and gastrointestinal issues that accumulate over years. The prospect of stopping medication and achieving treatment-free remission is appealing not just medically but psychologically, as it offers a sense of being truly done with the disease rather than perpetually managing it.

Access to Modern Therapies Is Uneven

The leukemia treatment revolution described above has mostly played out in wealthy countries. Tyrosine kinase inhibitors, CAR T-cell therapy, BTK inhibitors, and BCL-2 inhibitors are all expensive, and access varies enormously around the world. High costs, lack of insurance coverage, and out-of-pocket expenses for these drugs remain significant barriers to equitable cancer care globally. In settings where generic imatinib is available, CML outcomes have improved, but for the more recently developed targeted agents used in CLL, ALL, and AML, availability in low- and middle-income countries is patchy at best. A child diagnosed with ALL in a well-resourced pediatric oncology center and a child diagnosed in a country without access to intrathecal chemotherapy or adequate supportive care face fundamentally different odds, despite having the same disease.

1
Blood. Differences in Cell Cycle Characteristics Among Patients With Acute Nonlymphocytic Leukemia
2
PubMed Central. Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments
3
PubMed Central. Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?
4
PubMed Central. Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy
5
PubMed Central. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia
6
PubMed. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
7
PubMed Central. Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia
8
PubMed Central. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
9
PubMed Central. Targeted therapy in NPM1-mutated AML: Knowns and unknowns
10
PubMed Central. An approach to anxiety during watch-and-wait for Chronic Lymphocytic Leukemia: Monitor and move on
11
Journal of Interdisciplinary Medicine. Watch and Wait – Actualities in the Treatment of Chronic Lymphocytic Leukemia
12
Blood. Changing patterns and comparative outcomes of “watch-and-wait” versus immediate therapy in CLL: A propensity-weighted SEER analysis, 2000–2020
13
PubMed Central. Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice
14
PubMed Central. BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran
15
PubMed. BCR-ABL: The molecular mastermind behind chronic myeloid leukemia
16
PubMed Central. Treatment-Free Remission in Chronic Myeloid Leukemia
17
PubMed. Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
18
PubMed. Incidence and susceptibility to therapy-related myeloid neoplasms
19
PubMed Central. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
20
PubMed. Flow cytometry immunophenotyping and cytogenetic analysis on disaggregated bone marrow trephine biopsies
21
PubMed Central. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders
22
PubMed Central. Are incidence rates of adult leukemia in the United States significantly associated with birth cohort?
23
PubMed Central. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study